Items Tagged ‘Calquence acalabrutinib’

November 6, 2017

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma


The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive cancer and new treatments are needed for patients who have not responded to treatment or have relapsed, Mantle […]

View full entry

Tags: Calquence acalabrutinib, Lymphoma, mantle cell lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma